Status:
COMPLETED
Cangrelor Prasugrel Transition Study
Lead Sponsor:
The Medicines Company
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- greater than / equal to 18 and less than 75 years of age
- stable coronary artery disease defined by the following criteria
- Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic Q waves on at least 2 contiguous electrocardiogram (ECG) leads.
- OR
- Previous revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
- AND
- Treatment with aspirin (ASA) 81 mg daily.
Exclusion
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01852019
Start Date
June 1 2013
End Date
July 1 2013
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fletcher Allen Health Care
Burlington, Vermont, United States, 05401